About

Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Public Health,
  • The Pew Charitable Trusts

Profile

Elizabeth Jungman directs Pew’s work on public health, overseeing Pew’s initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse. 

Before joining Pew, she served as a senior health policy adviser with the Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures. 

Before moving to the Hill, Jungman was in private legal practice, where she counseled clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She has an undergraduate biology degree from Harvard College, a J.D. from Georgetown University, and a master’s degree in public health from Johns Hopkins University. 

Recent Work

View All
  • Opportunities for Drug Serialization to Make U.S. Drug Supply Chain Safer, More Secure

    As repackagers, shippers, and businesses at every link in the supply chain work with regulators to implement the law, they have the opportunity to use serial numbers to provide even stronger protections against counterfeit, tainted, or stolen drugs. Read More

  • Drug Compounding

    Traditional drug compounding—the creation of customized medicines to meet a patient's unique needs—has always been a part of pharmacy practice. But dramatic expansion of the sector in recent decades has resulted in production conditions on a scale closer to pharmaceutical manufacturing yet without the same oversight or quality standards. In fact, since 2001, over 25 pharmacy... Read More

  • Drug Shortages

    Drug shortages are an ongoing U.S. public health crisis. New annually reported incidents grew dramatically from 117 in 2007 to a high of 255 in 2011. Although such reports have begun to decline, unresolved drug shortages persist. In 2012, the United States experienced 456 active drug shortages, many of them crucial medicines used in cancer treatment, surgery, and intensive care. Read More

Media Contact

Linda Paris

Officer, Communications

202.540.6354